The research-grade biosimilar is a humanised recombinant IgG1 monoclonal antibody that specifically targets the scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. CD6 is a co-stimulatory molecule that is primarily expressed on the T-cell surface and plays an important role in the maturation, activation, and differentiation of T-cells, and pro-inflammatory cytokine production. Binding of Itolizumab to CD6 prevents T-cell activation, decreases the levels of IFN-γ, IL-6, and TNF-α and thus reduces inflammation. The original drug was approved by the DCGI in India to treat moderate-to-severe plaque psoriasis. In 2020, the drug received approval to treat moderate-to-severe COVID-19 complications.
In PBS, pH 7.5